logo

For the Inventor, By the Inventor

Tokyo, Japan

Chugai Pharmaceutical Co.

Calculating rank
USPTO Granted Patents = 14

% Expired Patents = 28.6


Forward Citations = 131

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Francisco Javier Lopez-Tapia (5 out of 38 patents)

silverMedal Sung-Sau So (5 out of 56 patents)

bronzeMedal Romyr Dominique (5 out of 21 patents)

4.  Kouji Matsushima (4 out of 39 patents)

5.  Yoshiki Yamada (3 out of 13 patents)

6.  Tatsumi Yamazaki (3 out of 10 patents)

7.  Yoshihiro Matsumoto (3 out of 6 patents)

8.  Masayuki Tsuchiya (3 out of 49 patents)

9.  Qi Qiao (3 out of 9 patents)

10.  Koh Sato (3 out of 19 patents)

11.  Yan Lou (2 out of 74 patents)

12.  Thomas J Gardella (2 out of 29 patents)

13.  John T Potts, Jr (2 out of 29 patents)

14.  Makoto Okazaki (2 out of 4 patents)

15.  Masaru Shimizu (2 out of 4 patents)


14 patents:

1. 11104668 - Inhibitors of bruton's tyrosine kinase (2021-08-31),
2. 10093657 - Inhibitors of bruton's tyrosine kinase (2018-10-09),
3. 9802920 - Inhibitors of bruton's tyrosine kinase (2017-10-31),
4. 9624201 - Inhibitors of bruton's tyrosine kinase (2017-04-18),
5. 9556150 - Inhibitors of bruton's tyrosine kinase (2017-01-31),
6. 9057727 - Screening methods using G-protein coupled receptors and related compositions (2015-06-16),
7. 8568737 - Screening methods using G-protein coupled receptors and related compositions (2013-10-29),
8. 6068840 - Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing (2000-05-30),
9. 6048972 - Recombinant materials for producing humanized anti-IL-8 antibodies (2000-04-11),
10. 6024956 - Method to treat inflammation with humanized anti-IL-8-antibodies (2000-02-15),
11. 5968784 - Method for analyzing quantitative expression of genes (1999-10-19),
12. 5866341 - Compositions and methods for screening drug libraries (1999-02-02),
13. 5707621 - Supression of nephritis-induced protein excretion by anti-IL-8 (1998-01-13),
14. 5464828 - Aqueous suspension of sucralfate (1995-11-07),
Company Overview
Chugai Pharmaceutical Co. is a leading biopharmaceutical company based in Tokyo, Japan, specializing in the research, development, and manufacturing of innovative medicines. The company focuses on therapeutic areas such as oncology, renal diseases, and autoimmune disorders, leveraging advanced biotechnology and pharmaceutical sciences. Chugai is committed to enhancing patient outcomes through cutting-edge research and collaboration with global partners, positioning itself as a key player in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

14 Patents

#1,599 in Tokyo

#3,583 in Japan

#42,293 in the World

Tokyo, JP
Tokyo, Japan

Chugai Pharmaceutical Co.

Forward Citations = 131

28 inventors:

goldMedal Francisco Javier Lopez-Tapia (5 out of 38 patents)

silverMedal Sung-Sau So (5 out of 56 patents)

bronzeMedal Romyr Dominique (5 out of 21 patents)

4.  Kouji Matsushima (4 out of 39 patents)

5.  Yoshiki Yamada (3 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Chugai Pharmaceutical Co.. Retrieved from https://idiyas.com/company/chugai-pharmaceutical-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…